Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Primary Target

CHEMBL1689064: Hydroxyl Radical

1

Histamine H1 receptor

316

Dopamine D2 receptor

311

DNA

282

Serotonin 2a (5-HT2a) receptor

237

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2017

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Acute ischemic stroke

1

Amyotrophic lateral sclerosis

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Mitsubishi Tanabe Pharma

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CHEBI

1

ChEMBL

1

DAILYMED

1

DRUG BANK

1

ECHA (EC/EINECS)

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

OTHER NERVOUS SYSTEM DRUGS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER NERVOUS SYSTEM DRUGS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other nervous system drugs

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 1 of 1 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

EDARAVONE

S798V6YJRP

Export Data
Search for Structure

Status:

US Approved Rx (2024)

First approved in 2017

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

CHEMBL1689064: Hydroxyl Radical

Conditions:

Acute ischemic stroke

Amyotrophic lateral sclerosis

Edaravone is a free radical scavenger developed for the treatment of amyotrophic lateral sclerosis.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1